Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation

Circulation

Volumn 126, Issue 13, 2012, Pages 1573-1576

  Gallego, Pilar ^a   Apostolakis, Stavros ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR RISK; CREATININE CLEARANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; EVIDENCE BASED PRACTICE; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; INVASIVE PROCEDURE; PEROPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

HEMORRHAGE; HEPARIN; HUMANS; PERIOPERATIVE CARE; THROMBOEMBOLISM; VITAMIN K;

EID: 84866725280     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.135681     Document Type: Editorial

References (20)

1. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:7S-47S.
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119-125. (Pubitemid 44420743)
3. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest. 2010;138:1093-1100.
4. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010;137:263-272.
5. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marín F, Palareti G, Kirchhof P; European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011;106:997-1011.
6. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marín F; European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010; 103:13-28.
7. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Consensus document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost. 2011;106:572-584.
8. Wysokinski WE, and McBane RD. Periprocedural bridging management of anticoagulation. Circulation. 2012;126:486-490.
9. Douketis JD. Contra: "Bridging anticoagulation is needed during warfarin interruption when patients require elective surgery." Thromb Haemost. 2012;108:210-212.
10. Spyropoulos AC. Pro: "Bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery." Thromb Haemost. 2012;108:213-216.
11. Siegal D, Yudin J, Kaatz, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: Systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126:1630-1639.
12. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: A systematic review. Arch Intern Med. 2003;163: 901-908. (Pubitemid 36522737)
13. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-1127.
14. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Manotti C; Italian Federation of Thrombosis Centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation: A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011;106: 868-876.
15. National Institutes of Health Clinical Center. A safety and effectiveness study of LMWH bridging therapy versus placebo bridging therapy for patients on long term warfarin and require temporary interruption of their warfarin (PERIOP2). ClinicalTrials.gov NCT00432796.
16. National Institutes of Health Clinical Center. Effectiveness of Bridging Anticoagulation for Surgery (the BRIDGE Study). ClinicalTrials.gov. NCT00786474.
17. Canadian Institutes of Health Research. Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial (BRUISECONTROL). ClinicalTrials.gov NCT00800137.
18. Tafur A, McBane R, Wysokinski WE, Slusser J, Hodge D, Heit JA. Predictors of periprocedural bleeding among patients on chronic anticoagulation. J Thromb Haemost. 2012;10:261-267.
19. Omran H, Bauersachs R, Rübenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation: Results from the national multicenter BNK Online bRiDging REgistRy (BORDER). Thromb Haemost. 2012;108:65-73.
20. Spyropoulos AC, Douketis DJ, Gerotziafas G, Kaatz S, Ortel TL, Schulman S, on behalf of the Subcommittee on Control of Antcoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Periporcedural antithrombotic and bridging therapy: Recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. J Thromb Haemost. 2012;10:692-694.